cardiopulmonary resuscitation
Conditions
Interventions
1:Simendan
Sponsors
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient's immediate relatives agree to sign the informed consent with the date indicated; 2. Aged 18-80 years old; 3. Cardiac arrest was first diagnosed by medical staff, and patients were hospitalized in Emergency Intensive Care Unit or emergency ward after recovery of spontaneous circulation of rescued patients (cardiopulmonary resuscitation/defibrillation/drugs); 4. From cardiac arrest to emergency intensive care unit or emergency ward hospitalization less than 24 hours; 5. Acute cardiac insufficiency (LEVF < 50%) occurred after recovery of autonomic circulation.
Exclusion criteria
Exclusion criteria: 1. Mechanical obstructive diseases, pericardial diseases such as primary valvular disease, hypertrophic cardiomyopathy or restrictive cardiomyopathy, cardiac rupture and cardiac tamponade that significantly affect ventricular filling or/or ejection function; 2. Pregnant and lactating women; 3. Cardiac surgery was performed within 30 days before screening; 4. Stroke and cerebral hemorrhage within 3 months before screening; 5. Systolic blood pressure continued to be lower than 85 mmHg at the time of examination or baseline; 6. Heart rate lasting 130 or more times at the time of examination or baseline; 7. Serum potassium was less than 3.5mmol/l during screening; 8. Patients allergic to levosimendan or any other excipient; 9. Patients with a history of torsional ventricular tachycardia; 10. Severe renal insufficiency (creatinine clearance 450 umol/l or dialysis); 11. Researchers decide at their discretion whether there is severe liver damage (alanine aminotransferase > 8-fold normal value upper limit or alanine aminotransferase > 3-fold normal value upper limit and total bilirubin > 2-fold normal value upper limit); 12. Severe anemia (hemoglobin < 8g/dl) and active hemorrhage; 13. Sepsis or septic shock; 14. Other serious diseases greatly limit life expectancy (e.g. advanced malignant tumors, severe brain contusion and laceration, multiple organ failure, and multiple trauma); 15. Participate in clinical trials of any experimental treatment within 3 months before screening, or in previous studies; 16. Levosimendan was used within 30 days before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients with the Pouchot score dropped by more than two points; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of laboratory indicators and clinical indicators; | — |
Countries
China
Contacts
Public ContactZhu Changqing
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed